Characterization and comparison of commercially available TNF receptor 2-Fc fusion protein products: Letter to the editor

mAbs

Volumn 5, Issue 5, 2013, Pages 624-625

  Hassett, Brian ^a   McMillen, Scott ^a   Fitzpatrick, Brian ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOSIMILAR AGENT; ETANERCEPT;

CLINICAL TRIAL (TOPIC); DRUG CONFORMATION; DRUG MARKETING; DRUG QUALITY; DRUG SAFETY; GLYCOSYLATION; HUMAN; IMMUNOGENICITY; LETTER;

ANIMALS; BIOSIMILAR PHARMACEUTICALS; FIBROBLASTS; HUMANS; IMMUNOGLOBULIN G; RECOMBINANT FUSION PROTEINS;

EID: 84883897104     PISSN: 19420862     EISSN: 19420870     Source Type: Journal    
DOI: 10.4161/mabs.25817     Document Type: Letter

References (4)

1. Tan Q, Guo Q, Fang C, Wang C, Li B, Wang H, et al. Characterization and comparison of commercially available TNF receptor 2-Fc fusion protein products. MAbs 2012; 4:761-74; PMID:23032066; http://dx.doi.org/10.4161/mabs.22276
2. Lee JF, Litten JB, Grampp G. Comparability and biosimilarity: considerations for the healthcare provider. Curr Med Res Opin 2012; 28:1053-8; PMID:22519391; http://dx.doi.org/10.1185/030079 95.2012.686902
3. Views on Public Policy. Biosimilars [Internet]. San Francisco (CA); Genentech: c2013 [cited 2013 May 28]. Available from: http://www.gene.com/about- us/views-on-public-policy/biosimilars.
4. Refusal assessment report for Alpheon [Internet]. London (UK); European Medicines Agency; c2006 [cited 2013 May 28]. Available from: http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Public-assessment- report/human/000585/WC500070792.pdf.